vs
AtriCure, Inc.（ATRC）与CANTALOUPE, INC.（CTLP）财务数据对比。点击上方公司名可切换其他公司
AtriCure, Inc.的季度营收约是CANTALOUPE, INC.的1.8倍（$141.2M vs $78.7M），AtriCure, Inc.净利率更高（0.1% vs -0.1%，领先0.2%），AtriCure, Inc.同比增速更快（14.3% vs 6.8%），过去两年AtriCure, Inc.的营收复合增速更高（10.2% vs 7.7%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
坎塔卢波（原美国技术公司）是一家美国科技企业，核心业务为ePort无现金支付受理技术，依托持专利的PCI合规ePort Connect服务开展运营。该服务可通过无线方式为消费者提供信用卡、借记卡以及Apple Pay、Google Pay等NFC钱包支付选项，同时为运营商提供遥测与机器间通信服务，ePort技术主要应用于...
ATRC vs CTLP — 直观对比
营收规模更大
ATRC
是对方的1.8倍
$78.7M
营收增速更快
ATRC
高出7.5%
6.8%
净利率更高
ATRC
高出0.2%
-0.1%
两年增速更快
ATRC
近两年复合增速
7.7%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $141.2M | $78.7M |
| 净利润 | $108.0K | $-70.0K |
| 毛利率 | 77.4% | — |
| 营业利润率 | 23.0% | 2.0% |
| 净利率 | 0.1% | -0.1% |
| 营收同比 | 14.3% | 6.8% |
| 净利润同比 | — | -101.4% |
| 每股收益（稀释后） | $0.00 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCCTLP
| Q1 26 | $141.2M | — | ||
| Q4 25 | $140.5M | $78.7M | ||
| Q3 25 | $134.3M | $80.9M | ||
| Q2 25 | $136.1M | $82.6M | ||
| Q1 25 | $123.6M | $75.4M | ||
| Q4 24 | $124.3M | $73.7M | ||
| Q3 24 | $115.9M | $70.8M | ||
| Q2 24 | $116.3M | $72.7M |
净利润ATRCCTLP
| Q1 26 | $108.0K | — | ||
| Q4 25 | — | $-70.0K | ||
| Q3 25 | $-267.0K | $-919.0K | ||
| Q2 25 | $-6.2M | $6.8M | ||
| Q1 25 | $-6.7M | $49.2M | ||
| Q4 24 | — | $5.0M | ||
| Q3 24 | $-7.9M | $3.6M | ||
| Q2 24 | $-8.0M | $2.2M |
毛利率ATRCCTLP
| Q1 26 | 77.4% | — | ||
| Q4 25 | 75.0% | — | ||
| Q3 25 | 75.5% | — | ||
| Q2 25 | 74.5% | — | ||
| Q1 25 | 74.9% | — | ||
| Q4 24 | 74.5% | — | ||
| Q3 24 | 74.9% | — | ||
| Q2 24 | 74.7% | — |
营业利润率ATRCCTLP
| Q1 26 | 23.0% | — | ||
| Q4 25 | 1.8% | 2.0% | ||
| Q3 25 | 0.2% | 2.0% | ||
| Q2 25 | -4.5% | 6.3% | ||
| Q1 25 | -4.8% | 9.1% | ||
| Q4 24 | -11.7% | 8.4% | ||
| Q3 24 | -6.4% | 5.8% | ||
| Q2 24 | -6.2% | 4.9% |
净利率ATRCCTLP
| Q1 26 | 0.1% | — | ||
| Q4 25 | — | -0.1% | ||
| Q3 25 | -0.2% | -1.1% | ||
| Q2 25 | -4.5% | 8.3% | ||
| Q1 25 | -5.5% | 65.2% | ||
| Q4 24 | — | 6.7% | ||
| Q3 24 | -6.8% | 5.0% | ||
| Q2 24 | -6.9% | 3.0% |
每股收益（稀释后）ATRCCTLP
| Q1 26 | $0.00 | — | ||
| Q4 25 | $0.04 | $0.00 | ||
| Q3 25 | $-0.01 | $-0.02 | ||
| Q2 25 | $-0.13 | $0.10 | ||
| Q1 25 | $-0.14 | $0.65 | ||
| Q4 24 | $-0.33 | $0.07 | ||
| Q3 24 | $-0.17 | $0.04 | ||
| Q2 24 | $-0.17 | $0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.2M | $53.0M |
| 总债务越低越好 | $61.0M | $37.7M |
| 股东权益账面价值 | $491.7M | $252.5M |
| 总资产 | $644.0M | $381.9M |
| 负债/权益比越低杠杆越低 | 0.12× | 0.15× |
8季度趋势，按日历期对齐
现金及短期投资ATRCCTLP
| Q1 26 | $146.2M | — | ||
| Q4 25 | $167.4M | $53.0M | ||
| Q3 25 | $147.9M | $55.0M | ||
| Q2 25 | $117.8M | $51.1M | ||
| Q1 25 | $99.9M | $46.3M | ||
| Q4 24 | $122.7M | $27.7M | ||
| Q3 24 | $130.3M | $33.1M | ||
| Q2 24 | $114.0M | $58.9M |
总债务ATRCCTLP
| Q1 26 | $61.0M | — | ||
| Q4 25 | — | $37.7M | ||
| Q3 25 | $61.9M | $38.3M | ||
| Q2 25 | $61.9M | $38.7M | ||
| Q1 25 | $61.9M | $39.2M | ||
| Q4 24 | — | $37.0M | ||
| Q3 24 | $61.9M | $37.3M | ||
| Q2 24 | $61.9M | $37.5M |
股东权益ATRCCTLP
| Q1 26 | $491.7M | — | ||
| Q4 25 | $491.9M | $252.5M | ||
| Q3 25 | $476.5M | $251.8M | ||
| Q2 25 | $464.5M | $251.0M | ||
| Q1 25 | $454.6M | $240.7M | ||
| Q4 24 | $461.0M | $190.1M | ||
| Q3 24 | $465.0M | $186.2M | ||
| Q2 24 | $462.1M | $181.7M |
总资产ATRCCTLP
| Q1 26 | $644.0M | — | ||
| Q4 25 | $654.2M | $381.9M | ||
| Q3 25 | $635.4M | $389.5M | ||
| Q2 25 | $608.8M | $381.9M | ||
| Q1 25 | $591.6M | $370.5M | ||
| Q4 24 | $609.3M | $303.0M | ||
| Q3 24 | $615.1M | $312.1M | ||
| Q2 24 | $597.3M | $335.6M |
负债/权益比ATRCCTLP
| Q1 26 | 0.12× | — | ||
| Q4 25 | — | 0.15× | ||
| Q3 25 | 0.13× | 0.15× | ||
| Q2 25 | 0.13× | 0.15× | ||
| Q1 25 | 0.14× | 0.16× | ||
| Q4 24 | — | 0.19× | ||
| Q3 24 | 0.13× | 0.20× | ||
| Q2 24 | 0.13× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $3.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-614.0K |
| 自由现金流率自由现金流/营收 | — | -0.8% |
| 资本支出强度资本支出/营收 | — | 4.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $25.8M |
8季度趋势，按日历期对齐
经营现金流ATRCCTLP
| Q1 26 | — | — | ||
| Q4 25 | $20.0M | $3.1M | ||
| Q3 25 | $26.7M | $7.0M | ||
| Q2 25 | $21.6M | $9.4M | ||
| Q1 25 | $-11.0M | $22.4M | ||
| Q4 24 | $5.8M | $522.0K | ||
| Q3 24 | $20.0M | $-12.0M | ||
| Q2 24 | $7.4M | $14.3M |
自由现金流ATRCCTLP
| Q1 26 | — | — | ||
| Q4 25 | $18.4M | $-614.0K | ||
| Q3 25 | $24.1M | $3.5M | ||
| Q2 25 | $19.0M | $4.3M | ||
| Q1 25 | $-13.2M | $18.6M | ||
| Q4 24 | $3.1M | $-3.8M | ||
| Q3 24 | $16.4M | $-15.8M | ||
| Q2 24 | $5.0M | $8.5M |
自由现金流率ATRCCTLP
| Q1 26 | — | — | ||
| Q4 25 | 13.1% | -0.8% | ||
| Q3 25 | 18.0% | 4.4% | ||
| Q2 25 | 13.9% | 5.3% | ||
| Q1 25 | -10.7% | 24.6% | ||
| Q4 24 | 2.5% | -5.1% | ||
| Q3 24 | 14.1% | -22.3% | ||
| Q2 24 | 4.3% | 11.7% |
资本支出强度ATRCCTLP
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 4.8% | ||
| Q3 25 | 1.9% | 4.2% | ||
| Q2 25 | 2.0% | 6.2% | ||
| Q1 25 | 1.8% | 5.1% | ||
| Q4 24 | 2.2% | 5.8% | ||
| Q3 24 | 3.1% | 5.4% | ||
| Q2 24 | 2.1% | 7.9% |
现金转化率ATRCCTLP
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.38× | ||
| Q1 25 | — | 0.46× | ||
| Q4 24 | — | 0.10× | ||
| Q3 24 | — | -3.36× | ||
| Q2 24 | — | 6.47× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage management | $48.4M | 34% |
| Open ablation | $39.1M | 28% |
| Other | $25.0M | 18% |
| Pain management | $22.4M | 16% |
| Minimally invasive ablation | $6.4M | 5% |
CTLP
| Transaction Processing | $47.9M | 61% |
| Subscription Revenue | $21.8M | 28% |
| Products | $9.0M | 11% |
